M13 Phage Engineering & Genome Editing
OverviewServicesSample RequirementsAdvantagesApplicationsCase StudyFAQs
Overview
Service Overview
M13 is a filamentous, non-lytic bacteriophage whose compact single-stranded DNA genome and highly ordered coat proteins have made it the workhorse of phage display, nanomaterial templating, and programmable microbial delivery. As a chronic, secretion-based phage, it replicates without lysing its host, enabling stable, high-titer propagation and precise surface engineering.
Creative BioMart Microbe provides M13 Phage Genome Editing built on three complementary routes: CRISPR-Cas9 counter-selection for high-efficiency mutant enrichment, reverse genetics using the double-stranded replicative-form (RF) DNA as a vector, and helper-phage systems such as M13KO7 for large-scale phagemid display. Each project is tailored from sequence design to validated, sequencing-confirmed phage.
Whether you need a pIII- or pVIII-display library for antibody screening, a coat-protein mutant for nanowire templating, or an M13 vector for CRISPR delivery to E. coli, our team matches the editing strategy to your target and host. Complementary capabilities, including phage display services and phage fermentation and large-scale production, link to adjacent capabilities for downstream development planning.
Figure 1. M13 phage genome editing platform overview — three complementary routes (CRISPR-Cas9 counter-selection, RF DNA cloning, and helper-phage packaging) tailored from sequence design to sequencing-confirmed phage delivery.
M13 Characteristics & Biological Background
Distinct from tailed lytic phages, M13 presents a filamentous architecture and a secretion-based life cycle that shape both its engineering and its applications.
| Attribute |
Detail |
| Filamentous morphology (Inoviridae) |
~6 nm diameter, 880–900 nm length; non-lytic secretion release forms characteristic cloudy plaques |
| Compact ssDNA genome |
~6.4 kb circular ssDNA encoding 11 genes (gI–gXI); double-stranded RF form used as a cloning vector |
| Display & scaffolding value |
pIII (low-copy, ~3–5 per virion) enables monovalent display of larger proteins; pVIII (high-copy, ~2,700 per virion) supports high-valency peptide display and ordered nanowire templating |
| Therapeutic delivery advantage |
Chronic infection without host lysis supports stable in vivo DNA delivery and strain-specific microbiome editing |
Services
Service Workflow
Each project moves through a four-stage pipeline — from target and vector design to multilayer validation — with the editing route customized to the intended fusion, mutation, or delivery goal.
Editing Strategies
We select among four established M13 editing routes to balance efficiency, cargo size, and downstream use.
| Strategy |
Mechanism |
Best For |
| CRISPR-Cas9 counter-selection |
Cas9 targets and cleaves the double-stranded replicative-form (RF) DNA of wild-type phage at protospacer-adjacent motif (PAM)-containing sites as negative selection pressure; edited phages that have undergone homologous recombination with a donor DNA construct and acquired mutations escaping cleavage are enriched |
Scarless point mutations, fusions, and knockouts from large wild-type backgrounds |
| Reverse genetics / RF cloning |
M13 double-stranded RF DNA used directly as a vector for restriction or Gibson assembly, then transformed to reboot phage |
Defined insertions, fusions, and genome streamlining |
| Helper-phage system |
M13KO7 and related helpers supply packaging proteins for phagemid libraries at scale |
Large-display libraries and high-titer phagemid production |
| Transformation optimization |
Electroporation protocols optimized for F′-bearing E. coli recipients (e.g., DH5α-F′) to enhance uptake of recombinant RF DNA and phagemid constructs |
Efficient rescue of bulky edited genomes |
Service Details
Gene Fusion / Insertion
Scarless insertion of peptide sequences (pVIII; typically <20 amino acids) or larger protein fragments (pIII; up to ~100 amino acids or antibody domains) at defined coat-protein loci, with infectivity assessed case by case. We design the fusion site and cloning strategy for your screening or nanomaterial goal, then deliver a sequenced, display-ready phage.
Site-Directed Mutation / Modification
Precise amino-acid substitution in key coat or receptor proteins (e.g., pVIII) to alter charge, binding affinity, or metal–semiconductor templating. Edits are introduced on RF DNA and rebooted, with Sanger confirmation of the mutant phage.
Functional Element Integration
Integration of compact promoters, reporter genes, or regulatory cassettes into available intergenic or engineered landing-pad sites, with viability and replication competence verified for each construct. This supports biosensing, tracer labeling, and CRISPR-cargo delivery constructs for microbiome applications.
Large-Fragment Deletion
Removal of auxiliary genomic segments to build genome-minimalized chassis phages with streamlined replication and higher cargo capacity. Deletions are designed to retain packaging and secretion competence, then validated by whole-genome sequencing.
Service Specifications & QC Standards
Deliverables & QC
- Plaque-purified, high-titer M13 lysate or phagemid preparation.
- Sanger or whole-genome sequencing confirmation of the edit or fusion.
- Western Blot verification of displayed / fused proteins where applicable.
- Wild-type background screening by PCR or sequencing, with off-target analysis scope defined per project based on edit type and client requirements.
- Project report with primer, sgRNA, or cloning sequences and methods.
Sample Requirements
To initiate a project, provide as much of the following as possible. Our team will advise on any gaps during the consultation.
| Required Information |
Optional Information |
Not Accepted |
- Target M13 phage (isolated lysate, deposited strain, or RF plasmid) and/or host E. coli strain
- Desired edit: gene fusion, point mutation, element integration, or large-fragment deletion, with target coordinates where known
- Intended application and downstream use (display screening, nanomaterial, delivery, vaccine)
|
- Existing genome sequence or annotation of the phage or host
- Preferred editing strategy or prior attempt data
- Display / selection protocols you want mirrored
|
- Pathogenic host strains or phages requiring BSL-2/3 containment without completed institutional biosafety committee (IBC) approval and import/export permits as required by destination jurisdiction
- Phages requiring BSL-3 handling unless pre-authorized
- Samples lacking any host or sequence context
|
Recommended Input Format by Edit Type
| Edit Type |
Preferred Input |
Typical Timeline |
| pIII / pVIII fusion |
M13 template + insert design |
3–5 weeks |
| Site-directed mutation |
M13 RF or lysate + target site |
2–4 weeks |
| Functional element integration |
M13 + cassette design |
3–5 weeks |
| Large-fragment deletion |
M13 genome map + deletion bounds |
4–6 weeks |
| Display library construction |
Phagemid vector + insert library |
4–6 weeks |
Lysates should be shipped on dry ice with glycerol backups; RF plasmid DNA is accepted in TE at 4°C. Contact our team via contact us before sending BSL-2 materials.
Our Advantages
- Enhanced enrichment efficiency — Our CRISPR-Cas9 counter-selection platform significantly increases the proportion of edited M13 phages in mixed populations, improving screening efficiency compared to conventional recombination methods.
- Customized design — We select the optimal fusion or mutation site for your goal, whether nanomaterial templating, antibody screening, or targeted delivery, rather than applying a single fixed scheme.
- Scarless editing — No unnecessary resistance markers are introduced, simplifying downstream biosafety documentation and reducing regulatory burden for preclinical development.
- Non-lytic stability — The secretion-based life cycle supports high-titer, stable propagation and in vivo DNA delivery without host lysis, simplifying scale-up and therapeutic use.
- Dual-display flexibility — Independent engineering of pIII and pVIII enables monovalent or high-valency presentation, supporting both affinity selection and multivalent nanomaterial or vaccine constructs.
Applications
Phage Display Library Construction
Exogenous peptide sequences inserted at the N-terminus of gIII or gVIII enable high-throughput screening of antibodies, peptides, and protein binders.
Nanomaterial Modification
Site-directed mutation of the pVIII major coat protein confers specific metal-binding or semiconductor-assembly capability for nanowires and biosensors.
Microbiome Precision Editing
Engineered M13 can deliver CRISPR-Cas systems to specific E. coli strains in vitro or in defined preclinical models, enabling strain-specific genetic modification research.
Novel Vaccine Development
Pathogen epitopes displayed on the phage surface generate particulate structures that have shown immunogenic potential in preclinical models, offering a platform for vaccine candidate development.
Case Study
Case Study 1: M13-Delivered CRISPR-Cas9 for Strain-Specific Gut Microbiome Editing
Engineered M13 bacteriophage delivered a plasmid-borne CRISPR-Cas9 system to F+ E. coli in the mouse gastrointestinal tract. In vitro, phage-delivered CRISPR-Cas9 caused impaired colony growth and induced chromosomal deletions ranging from 45 bp to 82.6 kb at the target locus. For in vivo work, streptomycin-treated mice were co-colonized with fluorescently marked isogenic strains and dosed with targeting or non-targeting control phage under carbenicillin selection for successful DNA delivery. The targeting phage significantly decreased GFP-marked cells relative to controls, achieving strain-specific depletion in 4 of 10 animals. Notably, bacterial escape through spacer loss, target-site mutations, and even deletion of the entire CRISPR-Cas9 system was observed, underscoring the need for refined delivery strategies. These findings establish M13 as a tractable vector for precision microbiome editing.
Figure 2. M13-delivered CRISPR-Cas9 for sequence-specific depletion of E. coli in the gut of mice colonized by competing fluorescently marked isogenic strains.
FAQs
Q: Why is M13 the preferred chassis for phage display and non-lytic engineering?
A: Unlike tailed lytic phages (T7, λ), M13 is a filamentous Inoviridae phage that assembles in the periplasm and is secreted without lysing its E. coli host. Its ~2,700 copies of pVIII and ~3–5 copies of pIII per virion support high-valency peptide display or lower-copy protein presentation; true monovalent display for affinity screening is achieved using phagemid systems with helper-phage supplementation.
Q: How does CRISPR-Cas9 counter-selection work on an M13 ssDNA genome?
A: Cas9 targets and cleaves the double-stranded replicative-form (RF) DNA of wild-type phage in the host, creating negative selection pressure. Only phages that have acquired edits through homologous recombination with a donor template—thereby altering the protospacer sequence—escape cleavage and are enriched, which we then confirm by Sanger sequencing.
Q: Can you engineer both pIII and pVIII display fusions on the same phage?
A: Yes. We routinely perform dual display — pIII for monovalent presentation of large proteins or antibodies (high intrinsic affinity) and pVIII for high-valency short peptides (avidity). The fusion sites and cloning strategy are selected for your screening or nanomaterial goal.
Q: What validation do you provide for an edited M13 phage?
A: Every project closes with multilayer validation: single-plaque PCR identification, Sanger sequencing of the edit or fusion, and Western Blot verification of displayed/fused proteins where applicable. We also perform wild-type background screening and deliver a full report with primer, sgRNA, or cloning sequences.
Q: How do you screen M13 mutants given that it forms cloudy plaques instead of clear lysis?
A: The non-lytic cycle means no clear plaque lysis, so we combine CRISPR counter-selection (mutants survive, wild-type is cleaved), optional resistance-marker selection, and plaque-morphology plus Western Blot checks. This lets us isolate recombinant phagemids and edited phage without relying on lysis-based screens.
Q: Can M13 be used to deliver CRISPR systems for microbiome editing?
A: Yes. As demonstrated in gut-microbiome studies, engineered M13 can transfer a programmable CRISPR-Cas9 cassette into target E. coli strains, enabling strain-specific depletion or chromosomal gene deletion. We design the cargo and packaging for preclinical and research applications.
Q: How do edited M13 phages transition to larger-scale production?
A: Validated edited M13 and recombinant phagemids hand off to our phage fermentation and large-scale production service, which operates documentation-ready, GMP-compatible workflows for therapeutic and industrial scale-up.
References:
- Lam, K. N., et al. (2021). Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. Cell Reports, 37(5), 109930. DOI: 10.1016/j.celrep.2021.109930
